Table 2.
Characteristics of Patients with myasthenia gravis undergoing strabismus surgery
| Pt | Age at Surgery (years) | Length of Follow-up (years) | Length of Disease Stability (years) | Thymectomy performed | Method of Diagnosis | Pre-op Medsa | Post-op Meds | Development of Generalized MG after initial presentation |
|---|---|---|---|---|---|---|---|---|
| 1 | 73.9 | 3.3 | 0.38 | No | Edrophonium (+) | None | Pyridostigmine | No |
| 2 | 9.7 | 10.7 | 1.26 | Not recorded | Edrophonium (+) | Pyridostigmine | Pyridostigmine | No |
| 3 | 55.6 | 10.6 | 1.84 | No | Edrophonium (+) | None | None | No |
| 4 | 62.7 | 3.1 | 0.58 | No | Clinical exam | Prednisone | None | Not recorded |
| 5 | 22.3 | 10.3 | 8.01 | Yes | AchRAb + | None | Pyridostigmine | Yes |
| 6 | 74.2 | 2.7 | 3.74 | No | Clinical exam | None | None | No |
| 7 | 72.6 | 1.5 | 0.10 | No | AchRAb+ | Pyridostigmine | Pyridostigmine | Yes |
| 8 | 39.1 | 8.1 | 2.00 | Yes | AchRAb+ | Pyridostigmine | Pyridostigmine | Yes |
| 9 | 38.5 | 0.7 | 0.16 | No | Clinical exam | Pyridostigmine | Pyridostigmine, prednisone | No |
a
Include only the medications the patient was taking immediately pre-operatively